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Introduction
Three-dimensional printing (3DP) has the potential to cause a paradigm shift in the way that medicines are designed, manufactured and used. For centuries, civilisation has experienced periodic radical transformations, often described as industrial revolutions. With the advent of steam engines, the textile industry and mechanised factories, the first industrial revolution was pronounced [1] . Motivated by the harnessing of electrical energy for mass production, the second industrial revolution evolved [2] . Subsequently, the third industrial revolution was established by the adoption of automation [3] .
Robotised and customised systems, such as cloud computing, the internet of things (IoT) and 3DP, have already been implemented to bridge the gap between the physical and virtual worlds [4] . Now, 3DP is at the forefront of the next industrial revolution.
3DP has created a technological paradigm by triggering boundless opportunities in diverse fields. It is an additive manufacturing technique that enables the fabrication of bespoke objects in a layered manner. By combining digitisation and mechanisation, this disruptive tool avoids the constraints often imposed by conventional tooling methods. Owing to its additive nature, 3DP delivers finalised products rapidly, with minimal waste production [5] .
Additionally, as the object designs are digitised, their customisation, storage and transference can be achieved with ease, avoiding the need for labour and space occupancy. Collectively, this permits the instantaneous creation of complex bespoke objects with ease. Thus, this singular platform has a multitude of applications ranging from aviation to automobiles, medicine, dentistry, art, jewellery, and footwear [6] .
In the pharmaceutical field, the drug development process is a multistage procedure, requiring a great deal of resources and time. Since the 1960s, this sector has been experiencing a dormant stage, whereby limited manufacturing advancements have been made. Recently, 3DP has offered contemporary opportunities to revolutionise the pharmaceutical industry. In particular, 3DP can be used to fabricate 'printlets', which is a term that refers to 3D printed solid oral dosage forms (e.g. tablets and capsules). As such, this multidisciplinary tool could be implemented in all the drug development stages, enhancing the quality of treatment in healthcare.
Whilst most research in this area is primarily focused on personalised medicines, a multitude of opportunities remain underexplored (Figure 1 ). In our previous review, we discussed the motivations and potential applications of 3DP in clinical research and practice, providing a practical viewpoint on its integration in a pharmaceutical setting, whilst highlighting the challenges and hurdles that come alongside [7] . In this review, we focus on the technical aspects, offering an overview on the novel prospects via which 3DP can be applied to the different drug development phases, including its discovery, early screening, testing, manufacturing, and dispensing, while discussing some of the technological hurdles associated with the adoption of these processing for pharmaceutical production.
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3D Printing to Support Drug Discovery
It is well understood that the drug failure rate is high during early phase continue to increase over the next decade. As such, there is a growing need for innovative technologies to support drug development, in particular, by enabling a rapid identification of suitable drug candidates at a minimal cost.
3DP could prove advantageous for this application by producing small or 'oneoff' batches of formulations (and even drugs) in a cost-effective, efficient and flexible manner. Using such technology could expedite the drug development process.
Early phase drug development covers the fields of drug discovery, pre-clinical studies and first-in-human (FIH) clinical trials. Within drug discovery, 3DP has already been used to produce active pharmaceutical ingredients (APIs).
Chemists from the University of Glasgow fabricated a series of reaction vessels (composed of polypropylene) using fused deposition modelling  Sheet lamination; which compromises the bonding of materials in the form of sheets (e.g. cut paper, plastic or metal) to fabricate 3D objects.
It is often known as laminated object manufacturing (LOM) or ultrasonic additive manufacturing (UAM).
 Material extrusion; which is a technology that involves the selective dispensing of material in a semi-solid form. This technology is further subdivided into fused deposition modelling (FDM), which utilises thermoplastics, and semi-solid extrusion (SSE), which utilises gels and pastes.
Insert figure 2 Whilst the 3DP technologies share some common features with one another and with other manufacturing technologies, such as injection moulding, the type of final products they are capable of fabricating differ inherently. As such, that for it to be considered cost-effective, the number of produced units should exceed a certain limit [23]. This limit is however, variable and is dependent upon multiple factors, including the size of the product, the build material and the number of moulds needed. Wherein, the number of moulds will vary depending on their lifetime, which in turn depends on their quality (e.g. material they are made from) and usage (e.g. number of uses and labour handling). As such, below the abovementioned limit, the cost of customising moulds exceeds the profit gained from fabricating the products. Hence, this finding highlights the main downside associated with the use of this technology. The 3DP technologies on the other hand do not necessitate the modification of tooling or require major labouring, which can possibly compensate for the high equipment pricing.
Similarly, whilst vat polymerisation and MJ processes are characterised with high precision and speed, they share two common demerits; high cost and their potential to cause toxicity due to the presence of unreacted monomers
[24]. Thus, for example, although the CLIP technology might be an ideal substitute for conventional tableting machines in terms of production speed, wherein it is capable of producing a tablet within seconds (this calculation is based on the fact that it takes CLIP ~6.5 min to produce the same object that takes ~3.5 hr and ~11.5 hr to be produced using SLS and SLA, respectively Thus far, only a few 3DP technologies have been investigated in pharmaceutical research with FDM being the most studied technique. This high prevalence is mostly attributed to the low costs and high availability of the printers. Conversely, in a case study where the unit prices were calculated using the same reference object, SLS, SLA, FDM and injection moulding costs were compared (Figure 3 ) [30] . Conclusively, all the 3DP technologies were found to result in a constant unit price throughout the production process, in which SLS was the most cost-efficient. Injection moulding on the other hand, provided a quantity-dependent curve, whereby below 2,000 production units, the cost was ~6-15 fold higher than that of the 3DP
technologies. This is mainly explained by the need for moulds in the case of injection moulding, wherein producing these moulds will require extra machinery, material and labour, hence the reason behind the increased cost.
Additionally, an important element, namely time, plays a major role in this scenario. As such, accelerating the speed of production results in the reduction of labour, resources and energy consumption, all of which collectively reduce costs. This provides sufficient proof that the machinery cost solely does not provide a summative evaluation to predict profit. In fact, currently, most injection moulding moulds are produced using 3DP, as it was found to reduce the total costs by ~24 fold (Redwood, B. 3D Printing low-run injection molds, https://www.3dhubs.com/knowledge-base/3d-printing-low-runinjection-molds; 2018 [accessed 02 February 2018]). Besides, it should be pointed out, that the abovementioned cost would further increase if the produced product is modified or changed (e.g. change in shape or size), as it will require the production of a new mould, whereas with the 3DP
technologies, this will only require the modification of the 3D design.
If the three 3DP technologies (FDM, SLA and SLS) were to be compared to one another, SLS can be considered to be more cost-effective than FDM and SLA ( Figure 3 ). Whilst this contradicts with what has been claimed in previous pharmaceutical papers, wherein the prevalent use of FDM was correlated with its apparent cost-effectiveness [31] , it is quite interesting to point out that in these calculations, the majority of the SLS cost accounts for the feedstock material. However, this is based on commercial feedstock and in pharmaceutical practice these numbers will differ inherently. This is because the feedstock utilised for SLS and FDM is identical and constitute a powder form of pharmaceutical grade excipients. In fact, the FDM feedstock will require further processing to produce filaments (e.g. the use of a hot melt extruder), which will further increase the cost of production.
As shown in Figure 3 , as the number of units increased, the injection moulding curve plateaued out at about 12,000 units, yielding a cost similar to that of SLS. This is because the gained profit starts to compensate for the added cost of the machinery utilised for moulds production. Arguably, it can be concluded that whilst 3DP would serve as an ideal solution for customised production on a small scale (e.g. on-demand dispensing of personalised therapy in a pharmacy or clinic), for large-scale production, conventional production technologies (such as, tableting machines or injection moulding)
would still remain superior.
Insert figure 3.
Economical and Logistical Benefits of 3D Printing Pharmaceuticals
3DP is forecast to become the single biggest disruptive technology to the global industry since assembly lines were introduced in the late 20 th century [32] . Within the pharmaceutical industry, the promise of 3DP includes transitioning tablet production from centralised towards decentralised facilities (e.g. within the clinic, local pharmacies or even in the patient's home). As such, 3DP could likely help move away from traditional mass manufacture, towards mass customisation or personalisation [32, 33] .
Decentralising pharmaceutical manufacture could provide three main benefits. and manufacturing processes, such as injection moulding [34] .
Second, it could offer a greater proximity to consumers, enabling quick and real-time responses to patient and market needs [35] . Local 3DP would be highly suited to the production of small batches of customised formulations.
Examples include medicines that have narrow therapeutic windows that require exact dosing [36] , or for complex formulations such as 'polypills' [37, 38] and those with unique geometries [19, 20, 39, 40] . 3DP could also be used to produce personalised objects that could be tailored to a patient's body and requirements [41] . For instance, a customised sternum and partial ribcage were successfully 3D printed and implanted into a cancer patient, The concept of digital dispensing using 3DP could also have applications in hard-to-reach areas, such as within disaster zones, third world countries or even in space [35, 42] . In 2017, the first medical supplies were 3D printed in space, whereby custom-fitted hand splint models were both designed and Third, as 3DP enables a precise spatial control over the deposition of materials, a reduction in the amounts of API and excipients needed could be achieved [34] . This concept could benefit high cost medicines, such as 'orphan drugs' that are developed for rare diseases (affecting less than 1 in 2000 people in Europe) [43] . Due to the relatively small patient populations treated, costs of orphan drugs can be extremely high, placing financial burdens on patients and healthcare systems. For example, the cost of ivacaftor for cystic fibrosis is in excess of $290,000 per patient per year [44] .
In this case, 3DP could be utilised to limit waste compared to conventional technologies and hence reduce costs of development and dosing.
Despite these benefits, it is clear that moving oral dosage form production towards local production (i.e. within clinical settings or at the patient's home)
could raise a number of regulatory, legal and ethical considerations [45] . In particular, the introduction of distributed manufacturing using 3DP will bring about new challenges, such as issues surrounding data security, raw material storage and transport, quality control and risk of counterfeit production [46] .
Moreover, the technical aspects of the 3DP process are yet to be well understood. For example, the reproducibility and accuracy of dosing (critical for narrow therapeutic index drugs) may be impacted by print resolution or homogeneity of mixing. In these instances, the use of technologies that provide high resolution (i.e. SLS and SLA [31] ), as well as the development of on-site quality control methods that are suitable for the 3DP process may be required to ensure safety [7] .
Current mass manufacturing facilities are governed by well-established good manufacturing practice (GMP) requirements to ensure patient and operator safety [47] . It is clear that new regulatory advice and guidance will be required before integration. Progress has already been made for additively manufactured medical devices, whereby the FDA released guidance detailing the technical considerations for such processes [48] . However, for 3DP of oral dosage forms, no such guidance has been released. As such, our research group at University College London (UCL) has initiated discussions with regulatory bodies to further advance the technology for this application.
From an economical perspective, it is likely that the production of high-volume and low-added value pharmaceuticals will remain more efficient in centralised manufacturing hubs. This is because the economies of scale of 3DP will likely never reach the same level as mass production [49] . However, there is value in scaling up 3DP processes, wherein personalisation is a requirement (e.g.
implants and prosthesis). For example, several major manufacturers use 3DP
to produce hearing aids in fairly large volumes (~1000 devices/day), each being unique in shape and size [49] . Theoretically, similar principles could be applied to pharmaceuticals, whereby formulation shape, size, dosage and drug content could be adapted to suit the patient therapeutic needs and preferences. As such, this could facilitate patient autonomy in the treatment pathway, leading to increased medication adherence and therapeutic outcomes, as well as reduced wastage.
Conclusion
We stand on the brink of a revolution, where novel technologies such as 3DP
are likely to cause a paradigm shift in pharmaceutical manufacture and supply. To date, the long-term benefits of this technology have been forecasted to lie within personalised medicines, leaving a wide range of opportunities underexplored. Indeed, 3DP could also provide many other advantages, ranging from applications in drug discovery, formulation manufacturing processes, global supply and logistics. In the future, 3DP could be used as a digital dispensing tool, supporting operations in hard-to-reach areas such as disaster zones and even within space. Indeed, the adoption of this highly disruptive technology will likely reshape the way that we design, manufacture and use medicines.
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